Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Wilms Tumor 5Sarcoma 3Neuroblastoma 3Carcinoma, Renal Cell 3Testicular Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Retinoblastoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Triple Negative Breast Neoplasms 1Testicular Germ Cell Tumor 1Sarcoma, Clear Cell 1Rhabdoid Tumor 1Prostatic Neoplasms 1Optic Nerve Glioma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Hepatoblastoma 1Head and Neck Neoplasms 1Fibrosarcoma 1Familial ependymoma 1Fallopian Tube Neoplasms 1

Interventions

Docetaxel 292Prednisone 241enzalutamide 195Leuprolide 185Radiotherapy 179Abiraterone Acetate 170Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 93abiraterone 83gallium 68 PSMA-11 81Specimen Handling 73darolutamide 67Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 53Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Topotecan × Genitourinary × Clear all
NCT00084565 2013-07-10

Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer

Fox Chase Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡